LISTING OF THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-4. (canceled)

- 5. (currently amended) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: of SEQ ID NO: 14.
 - a mature form of the amino acid sequence given SEQ-ID NO: 14;
 - a variant of a mature form of the amino acid sequence of SEQ-ID-NO: 14, wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
 - the amino acid sequence of SEQ ID NO: 14;
 - -a variant of the amino acid sequence of SEQ ID NO: 14, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed;
 - a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence of SEQ ID NO: 14, or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and
 - the complement of any of said nucleic acid molecules.
- 6. (currently amended) The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant SEQ ID NO: 13.

7. – 11. (canceled)

12. (currently amended) A vector comprising the nucleic acid molecule of elaim 11 claim 5.

- 13. (original) The vector of claim 12, further comprising a promoter operably linked to said nucleic acid molecule.
- 14. (currently amended) [[A]] An isolated cell comprising the vector of claim 12.
- 15. 26. (canceled)
- 27. (currently amended) A pharmaceutical composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically acceptable carrier.
- 28. 29. (canceled)
- 30. (original) A kit comprising in one or more containers, the pharmaceutical composition of claim 27.
- 31. 35. (canceled)
- 36. (new) An isolated nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO:13.
- 37. (new) An isolated polynucleotide comprising a fragment of the nucleic acid sequence of SEQ ID NO:13, wherein the fragment encompasses a nucleotide corresponding to position 278 of SEQ ID NO: 13.
- 38. (new) The isolated polynucleotide of claim 37, wherein the nucleotide is T.